| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief R&D Officer
1 company
Zalevsky Jonathan is a Chief R&D Officer at NEKTAR THERAPEUTICS. Recent SEC Form 4 filings include 0 buys and 13 sells.
Estimated insider holdings value: $2.1M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 1,157 | $54.28 | $62,801.96 | -5.7% | +21.9% | - | |
| Sep 4, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 1,721 | $33.52 | $57,692.51 | -2.3% | +58.8% | - | |
| Sep 2, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 485 | $30.10 | $14,598.50 | -2.5% | +110.1% | - | |
| Aug 19, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 725 | $26.59 | $19,277.75 | -3.6% | +123.0% | - | |
| May 19, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 10,712 | $0.67 | $7,177.04 | -3.4% | +163.1% | - | |
| Feb 19, 2025 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 10,300 | $1.01 | $10,403.00 | -3.2% | -31.3% | +392.4% | |
| Dec 19, 2024 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 51,115 | $0.94 | $48,048.10 | -13.5% | -4.7% | +231.8% | |
| Nov 19, 2024 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 7,785 | $1.01 | $7,862.85 | -3.1% | +2.9% | +290.6% | |
| Aug 19, 2024 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 6,866 | $1.28 | $8,788.48 | -2.7% | -22.6% | +33.9% | |
| May 17, 2024 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 7,355 | $1.75 | $12,871.25 | -2.8% | -32.2% | -61.0% |